BioCentury
ARTICLE | Company News

Hemosol submits FDA amendments

September 13, 2001 7:00 AM UTC

Hemosol (HMSL; TSE:HML) submitted to the FDA proposed design amendments for its Hemolink Phase III trials in the U.S. The announcement follows a verbal communication from the FDA, in which the agency ...